TrialCancer2024

Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.

Emily M Hinchcliff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.